SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

7.47
USD
-0.39
(-4.96%)
-0.21EPS
2.98BMarket Cap
Mar 25Next Earn

Total Valuation

USD

As of June 30, 2026, SELLAS Life Sciences Group, Inc. carries a market capitalization of 2.98B, placing it among publicly traded companies globally. Its enterprise value stands at 2.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.98B
Enterprise Value2.84B

Important Dates

SELLAS Life Sciences Group, Inc.'s next confirmed earnings release is scheduled for March 25, 2027.

Earnings Date3/25/2027

Share Statistics

As of June 30, 2026, SELLAS Life Sciences Group, Inc. has 201.92M shares outstanding.

Shares Outstanding201.92M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio21.65
P/TBV Ratio21.96
P/FCF Ratio-80.90
P/OCF Ratio-80.90

Financial Position

As of June 30, 2026, SELLAS Life Sciences Group, Inc. maintains a current ratio of 18.83, meaning it holds 18.8x the short-term assets needed to cover near-term liabilities.

Current Ratio18.83
Quick Ratio18.28
Debt / Equity0.54
Debt / EBITDA-0.02

Financial Efficiency

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. posted a negative return on equity (ROE) of -39.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.54, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.50, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-39.63
Return on Assets (ROA)-36.54
Employee Count13.50

Stock Price Statistics

USD

As of the close on November 16, 2026, SELLAS Life Sciences Group, Inc.'s stock has gained approximately 422.38% over the past 52 weeks. The 50-day moving average sits at 10.90, while the 200-day moving average is 8.80.

52-Week Price Change422.38%
50-Day Moving Average10.90
200-Day Moving Average8.80

Income Statement

USD

Over the twelve months ended June 30, 2026, SELLAS Life Sciences Group, Inc. generated - - in revenue and converted that into -32.46M in net income, yielding earnings per share of -0.21. EBITDA reached -35.22M, while operating income came in at -35.22M.

Operating Income-35.22M
Pretax Income-32.46M
Net Income-32.46M
EBITDA-35.22M
EBIT-35.22M
Earnings Per Share (EPS)-0.21

Balance Sheet

USD

As of June 30, 2026, SELLAS Life Sciences Group, Inc. holds 138.34M in cash and equivalents against 737,000.00 in total debt, resulting in a net debt position of -138.34M. Total book value stands at 137.66M, with working capital of 134.94M providing operational flexibility.

Cash & Cash Equivalents138.34M
Total Debt737,000.00
Net Debt-138.34M
Equity (Book Value)137.66M
Book Value Per Share0.68
Working Capital134.94M

Cash Flow

USD

SELLAS Life Sciences Group, Inc. produced -28.42M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-28.42M
Free Cash Flow-28.42M
FCF Per Share-0.18

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.75, meaning SELLAS Life Sciences Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-4.75
FCF Yield-1.24

Stock Splits

SELLAS Life Sciences Group, Inc.'s most recent stock split took place on November 8, 2019 with a 50:1 split ratio.

Last Split Date11/8/2019
Split Ratio50:1

Scores

As of June 30, 2026, SELLAS Life Sciences Group, Inc. has an Altman Z-Score of 228.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score228.91